SAF from COPD subjects were treated with 50 μg/mL of either isotype control or an antibody that binds the IL-36R and blocks signaling, followed by 100 ng/ mL of IL-36γ. The gene discussed is IL36G; the disease is chronic obstructive pulmonary disease.